In summary, our urine results indicate that weight loss through GLP-based therapies is not associated with prolithogenic changes in 24-hour urine chemistry in patients with nephrolithiasis, unlike what happens with alternative weight loss modalities (such as malabsorptive bariatric surgery and pharmacological therapy with orlistat or topiramate)
Risks of Delay Waiting too long can prolong fatigue, discomfort, and poor sleep, yet the concern goes further
Real-world combination scenarios Understanding the research is one thing
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight without type 2 diabetes and tracked them over 72 weeks
Systemic adverse events remain rare in available trials, though long-term safety data in non-dermatology populations is sparse
1 T2DM is a progressive disorder characterized by insulin resistance and a progressive insulin secretory defect